{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:17:39Z","timestamp":1790713059615,"version":"4.1.0"},"reference-count":196,"publisher":"Baishideng Publishing Group Inc.","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2021,6,7]]},"DOI":"10.3748\/wjg.v27.i21.2727","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T04:51:45Z","timestamp":1622004705000},"page":"2727-2757","source":"Crossref","is-referenced-by-count":45,"title":["Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure"],"prefix":"10.3748","volume":"27","author":[{"given":"Efthymios P","family":"Tsounis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Tourkochristou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Mouzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"B2","unstructured":"World Health Organization.   Hepatitis B. WHO Fact sheets. 27 Jul 2020. [cited 10 January 2021]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1281"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13635"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.003"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0037-0"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30168-9"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.014"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309809"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i27.3527"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21896"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28013"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00096-07"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00873-12"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000741"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000563"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.009"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.01491"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-017-9829-7"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01232-09"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.66.7.4107-4116.1992"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05373-11"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.7.4269-4274.1996"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0704000104"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312162"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061486"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.1703.03066"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.03.006"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis273"},{"key":"B33","doi-asserted-by":"crossref","unstructured":"Petcu DJ, Aldrich CE, Coates L, Taylor JM, Mason WS. Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology 1988; 167: 385-392","DOI":"10.1016\/S0042-6822(88)90099-2"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4828936"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28952"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03478-13"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.12.008"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2965"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26982"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.11.009"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30651-6"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.009"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243462"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz143"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.09.026"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30086-6"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.20"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/srep10833"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.212"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.94"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)32126-7"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31578"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58847"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M606774200"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31855-X"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)31226-1"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nature17170"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2018.10.010"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1339"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30491"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.26125"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217433"},{"key":"B63","unstructured":"Rawal PR, Tripathi DM, Sarin SK, Nain V, Kaur S. Targeting HBx by CRISPR\/Cas9 system effectively reduced the EMT and stemness characteristics of HCC cells in vitro. Hepatology  2020; 72 Suppl 1: 61A"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.14304\/surya.jpr.v4n7.5"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31008"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30597-3"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30647-4"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31850-0"},{"key":"B69","unstructured":"Yuen MF, Berliba E, Kim YJ, Holmes JA, Lim Y-S, Strasser SI, Schwabe C, Jucov A, Lee ACH, Thi EP, Harasym T, Pamulapati GR, Wattamwar P, Kunta J, Sofia M, Sevinsky H, Gray K, Eley T, Picchio G, Sims KD, Gane E. Safety and Pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with Chronic Hepatitis B infection. Hepatology 2020; 72 Suppl 1: 62A-63A"},{"key":"B70","unstructured":"Yuen MF, Lim TH, Kim W, Tongkijvonich P, Yoon JH, Sievert W, Sukeepoisornjoroen W, Thompson A, Schwabe C, Brown B, Achnecl H, Gane E.   HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels. Late breaking abstract to the AASLD\u2019s The Liver Meeting\u00ae Digital Experience\u2122 2020; American Association for the Study of Liver Diseases, 2020: 14"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.670"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30646-2"},{"key":"B73","unstructured":"You S, Yates P, Elston R, Tao Y, Paff M, Theodore D.   Short-term therapy with GSK3228836 in chronic hepatitis B (CHB) patients results in reductions in HBcrAg and HBV RNA: Phase 2a, randomized, double-blind, placebo-controlled study. Late breaking abstract to the AASLD\u2019s The Liver Meeting\u00ae Digital Experience\u2122 2020; American Association for the Study of Liver Diseases, 2020: 52"},{"key":"B74","unstructured":"Hong J, Tan H, Lin T-I, Kang H, Nie Y, Bhattacharya A, Rajendra P, Blatt LM, Symons JA, Beigelman LN. Combination of Antisense Oligonucleotides (ASOS) ALG-020572 and ALG-020576 against Hepatitis B Virus (HBV) improves activity and can be combined with other anti-HBV agents. Hepatology 2020; 72 Suppl 1: 63A"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30648-6"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31579"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.014"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.11.009"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.06.020"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00269"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006658"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30964-8"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01686-19"},{"key":"B84","unstructured":"Tai Z, Tian Q, Zhao X, Xie J, Lu Y, Tan Y, Zhao W, Ma X, Yuan X, Song H, Xue T, Wang J. Discovery of KL060332, a potential best-in-class capsid inhibitor. Hepatology  2020; 72 Suppl 1: 504A"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.023"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02439-19"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30773-X"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30649-8"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30790-X"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30767-4"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra031087"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/srep43838"},{"key":"B93","unstructured":"Bazinet M, Anderson M, P\u00e2ntea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Vaillant A. Analysis of HbsAg isoforms during and after NAP-based combination therapy in the REP 301, REP 301-LTF and REP 401 studies. Hepatology  2020; 72 Suppl 1: 500A-501A"},{"key":"B94","unstructured":"Nie Y, Tan H, Kao C, Ren S, Pandey R, Chanda S, Blatt L, Beigelman LN, Symons JA, Hong J. S-Antigen Traffic-Inhibiting Oligonucleotide Polymers (STOPs) Effectively Inhibit Hepatitis B Surface Antigen (HbsAg) Secretion in Both Hepatitis B Virus (HBV) Cell Lines and HBV Infected Cells. Hepatology 2020; 72 Suppl 1: 502A-503A"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.058"},{"key":"B96","unstructured":"Gohil V, Misner D, Chanda S, Zhang Q, Liu J, Hong J, Pandey R, Rajwanshi VK, Williams C, Yogaratnam J, Fry J, Smith DB, Symons JA, Blatt LM, Beigelman LN, Lin TI. The S-Antigen Transport-Inhibiting Oligonucleotide Polymer (STOPS\u2122) ALG\u2010010133 Demonstrates a Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B. Hepatology 2020; 72 Suppl 1: 508A"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.1.68-76.2003"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00867-09"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29082"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.011"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-0325-6"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2011.05.039"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03007"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.04.006"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00396-05"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026315"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21897"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.05.004"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.003"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.11.7269-7272.2005"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.026"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.027"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.01.030"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1420"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1397"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12791"},{"key":"B117","unstructured":"Wu L, Niu J, Gane EJ, Slaets L, Creus AD, Ding Y, Schwabe C, Goeyvaerts N, Xu Z, Huo D, Remoortere PV, Schwertschlag U, Vandenbossche JJ. Population pharmacokinetic\/pharmacodynamic (PK\/PD) models of JNJ-64794964, a toll-like receptor (TLR)-7 agonist in healthy adult subjects. Hepatology 2020; 72 Suppl 1: 506A"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02275-2"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1259"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31255"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00100"},{"key":"B122","unstructured":"Janssen HL, Lim YS, Kim HJ, Tseng CH, Coffin CS, Elkhashab M, Anh SH, Nguyen AH, Chen D, Wallin JJ, Tan SK, Yang JC, Gaggar A, Brainard DM, Fung S, Kim YJ, Kao JH, Chuang WL. Safety and efficacy of 24 wk treatment with oral TLR8 agonist, Selgantolimod, in viremic adult patients with chronic Hepatitis B: a phase 2 study. Hepatology  2020; 72 Suppl 1: 506A-507A"},{"key":"B123","unstructured":"Baum P, Odegard V. ASGR1-TLR8, an ASGR1-directed TLR8 Immunotac(TM) therapeutic, is a potent myeloid cell agonist with liver-localized activity for the treatment of chronic HBV. Hepatology 2020; 72 Suppl 1: 503A"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0288-3"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00009.2014"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/srep26150"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nri2851"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161313"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30084-2"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1566"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2019.03.013"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04321-14"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2009.138"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.42"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-019-0309-9"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055318"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33402"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121172"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.S12-004"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250631"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.11.002"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.10.025"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104748"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.02.001"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120228"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182829903"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211714"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191663"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31503"},{"key":"B151","unstructured":"Leonard S, Paterson R, Godinho L, Howe D, Monteiro M, Hague RM, Atkin K, Sarkar A, Suckling R, Bunjobpol W, Kay D, Grant T, Perot C, Knox A. Novel HLA-E specific ImmTAVR molecules for the treatment of Hepatitis B. Hepatology 2020; 72 Suppl 1: 59A-60A"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00310"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014567469"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014567470"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/celldisc.2017.4"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00617"},{"key":"B158","unstructured":"Hasanpourghadi M, Luber A, Magowan C, Zhou X, Ertl H. Glycoprotein D, a checkpoint inhibitor of early T cell activation, broadens HBV T cell antigen recognition and produces sustained antiviral declines in preclinical studiesa. Hepatology 2020; 72 Suppl 1: 505A"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30572-9"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2020.9.1.1"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.09.072"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2039"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2017.03.011"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12530"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23113044"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144383"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30944-2"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1651141"},{"key":"B169","unstructured":"Vaccitech Ltd.   First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients. 2020 June 23. [cited 20 September 2020]. In: B3C newswire [Internet]. Available from: https:\/\/www.vaccitech.co.uk\/first-participant-dosed-in-phase-1-clinical-study-with-vtp-300-immunotherapeutic-to-treat-chronically-infected-hepatitis-b-patients\/"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/nm1212"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30090-8"},{"key":"B172","unstructured":"Altimmune Inc.   Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell\u2122 Immunotherapeutic for the Treatment of Chronic Hepatitis B. 2020 June 22. [cited 25 September 2020]. In: GlobeNewswire [Internet]. Available from: https:\/\/www.globenewswire.com\/news-release\/2020\/06\/22\/2051121\/0\/en\/Altimmune-Announces-IND-Clearance-for-a-Phase-2-Trial-of-HepTcell-Immunotherapeutic-for-the-Treatment-of-Chronic-Hepatitis-B.html"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.03.044"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12334"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606593"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/nri2765"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1689080"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1335840"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002565"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200501"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70166-3"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0095-z"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201236"},{"key":"B184","doi-asserted-by":"crossref","unstructured":"Yoshida O, Imai Y, Shiraishi K, Tokumoto Y, Sanada T, Kohara-Tsukiyama K, Miyazaki T, Kamishita T, AI Mahtab M, Aguilar JC, Guillen Ge, Fazle Akbar SM, Kohara M, Hiasa Y. HBsAg reduction by nasal administration of a therapeutic vaccine containing HBsAg and HBcAg (Nasvac) in patients with chronic HBV infection: the result of 18 mo follow up. Hepatology 2020; 72 Suppl 1: 80","DOI":"10.1016\/S0168-8278(20)32212-1"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)32209-1"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)31615-9"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.29245\/2578-3009\/2018\/2.1118"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.010"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0395-0"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-020-0648-y"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00191"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00082-18"},{"key":"B193","unstructured":"Zhang Q, Jekle A, Serebryany V, Welch M, Liu J, Vendeville S, Debing Y, Buh Kum D, Ren S, Liu C, Deval J, Misner D, Chanda S, Mukherjee S, Raboisson P, Symons JA, Blatt LM, Biegelman LN, Smith DB. Best in class preclinical characteristics of ALG-000184, a prodrug of the capsid assembly modulator ALG-001075 for the treatment of chronic hepatitis B. Hepatology 2020; 72 Suppl 1: 503A"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01701-19"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1128\/aac.46.9.3057-3060.2002"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00346"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v27\/i21\/2727.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T04:53:26Z","timestamp":1622004806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v27\/i21\/2727.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":196,"journal-issue":{"issue":"21"},"URL":"https:\/\/doi.org\/10.3748\/wjg.v27.i21.2727","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,7]]}}}